In a significant advancement for global pediatric health, the U.S. Food and Drug Administration (FDA) has officially granted approval to ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in pediatric patients weighing as little as 2 kg (approximately 4.4 pounds). This decision effectively removes the minimum-age requirement for the medication, allowing for its use in newborns from birth. The approval marks a critical turning point in the management of perinatally acquired HIV, providing clinicians with a robust, second-generation integrase strand transfer inhibitor (INSTI) tailored specifically for the most vulnerable demographic.
Main Facts: Expanding the Therapeutic Toolkit
The FDA’s latest authorization represents a pivotal expansion of the existing Tivicay PD label. Previously, the dispersible tablet formulation was restricted to infants at least four weeks old and weighing a minimum of 3 kg (6.6 lbs). By lowering the weight threshold to 2 kg and eliminating the age floor, ViiV Healthcare—a global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders—is addressing a long-standing "treatment gap."
Tivicay PD is intended for use in combination with other antiretroviral agents. It is indicated for both treatment-naive patients and those who are treatment-experienced but have not previously been exposed to integrase inhibitors. This versatility is essential in clinical settings where rapid initiation of antiretroviral therapy (ART) is the standard of care to suppress viral load and prevent the devastating complications of untreated HIV in infants.
Chronology of Development: From Adult Therapy to Neonatal Care
The journey to this approval reflects the broader evolution of HIV pharmacotherapy.
- August 2013: The FDA granted its initial approval for Tivicay (dolutegravir) for use in adults and adolescents aged 12 or older with a minimum body weight of 40 kg (88.2 lbs). At the time, the focus was primarily on simplifying adult regimens and overcoming resistance issues associated with older drug classes.
- 2020: Recognizing the need for pediatric-friendly formulations, the FDA approved the dispersible tablet (Tivicay PD) for infants and children at least four weeks old and weighing 3 kg or more.
- 2025 (CROI): Preliminary data from the IMPAACT 2023 study was presented at the Conference on Retroviruses and Opportunistic Infections (CROI), providing the clinical evidence base required to support the safety and efficacy of the drug in the first days of life.
- August 2026: The FDA officially granted expanded approval, bolstered by Priority Review, marking the drug’s transition into neonatal care.
Supporting Data: The IMPAACT 2023 Study
The clinical evidence underpinning this approval stems from the NIH-funded IMPAACT 2023 multicenter, phase 1 clinical trial. The study was meticulously designed to establish the pharmacokinetics (PK), safety, and tolerability of dolutegravir during the most critical window: the first four to six weeks of life.
The trial enrolled 48 mother-infant pairs across clinical sites in the United States, South Africa, and Thailand. Infants weighing at least 2 kg received Tivicay PD starting from birth for up to six weeks, alongside the standard-of-care antiretrovirals typically used to prevent vertical (mother-to-child) transmission.
Key findings from the trial included:
- Efficacy and PK: The drug levels observed in newborns were consistent with those seen in adults, which are well-established to provide robust viral suppression.
- Safety Profile: The safety and tolerability profile was comparable to that observed in older pediatric and adult populations, with no unexpected safety signals during the 16-week follow-up period.
- Dosing Nuance: Data from a 15-infant chronic-dosing cohort demonstrated that full-term infants (weighing 2.3 to 3.6 kg) could successfully transition to a 5-mg tablet every other day for the first two weeks, followed by daily dosing, ensuring optimal drug concentration as the infant’s metabolism matures.
Official Responses and Clinical Perspectives
The medical community has hailed the approval as a long-awaited victory. Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and the lead investigator of the IMPAACT 2023 study, emphasized the gravity of the change.
"For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Dr. Clarke stated. "This is an important advance for the care of newborns."
The FDA’s decision to grant Priority Review underscores the agency’s recognition of the urgent need for therapeutic options that can be administered immediately following birth. By providing a validated, age-appropriate dosage, the FDA is helping to minimize the "guesswork" that clinicians often face when adapting adult medications for neonatal use.
Implications for Public Health and the HIV Landscape
While perinatally acquired HIV infections in the United States have become relatively rare—numbering fewer than 50 cases annually since 2018—the global implications of this approval are profound. UNICEF reports that approximately 50% of infants living with HIV will die before their second birthday if they do not receive treatment.
The Financial and Market Context
The approval of Tivicay PD arrives at a time when ViiV Healthcare is managing a shifting product portfolio. While the standalone Tivicay brand has seen sales plateau—recording £1.323 billion in 2025, a slight decrease from the previous year—the company’s broader HIV portfolio continues to demonstrate resilience.
GSK’s total HIV franchise generated £7.687 billion in 2025, driven by an 11% growth in newer, long-acting products like Cabenuva and Apretude, as well as the oral combination therapy Dovato. The introduction of Tivicay PD for the youngest patients serves as a strategic cornerstone, reinforcing the company’s commitment to the entire lifecycle of HIV management. It ensures that even as the company pivots toward long-acting injectable therapies for adults, it remains the gold standard for foundational oral care in pediatric populations.
Future Challenges and Opportunities
Despite this success, the fight against pediatric HIV remains multifaceted. The primary challenge remains the identification of HIV-exposed infants and ensuring they enter the care continuum immediately. While the transmission rate in the U.S. has been successfully suppressed to 1% or less, global health initiatives must now leverage this new approval to reach underserved populations in low- and middle-income countries where vertical transmission remains a persistent health crisis.
The availability of a dispersible tablet that can be used from birth provides a logistical advantage in resource-limited settings, where complex liquid formulations may be difficult to store or transport. The simplicity of a tablet that can be dissolved in water or breast milk aligns with the operational realities of global health providers.
Conclusion
The FDA’s approval of Tivicay PD for newborns weighing at least 2 kg is a landmark development that underscores the value of pediatric-focused clinical research. By integrating advanced pharmacokinetic modeling with rigorous clinical trials, ViiV Healthcare has successfully bridged a critical gap in the HIV treatment spectrum. As pediatric HIV becomes an increasingly manageable condition, the availability of such specialized therapies is essential to ensuring that no child, regardless of birth weight or age, is left without the benefit of modern, life-saving medicine. This approval not only validates the efficacy of dolutegravir but also sets a higher standard for the inclusion of neonates in future drug development initiatives.
About the Author
